Firstly, different studies had their own varied expression cut-off values, which brought many difficulties for us to define the standard cutoff value, resulting in bias in the results of the effectiveness of galectin-3 as a prognostic factor in cancer patients. The gene discussed is LGALS3; the disease is cancer.